Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection
Business Wire - Tue Sep 23, 11:00PM CDT
-- Ledipasvir/Sofosbuvir Simplifies Hepatitis C Treatment to a Single, Once-Daily Tablet --
Final Glance: Biotechnology companies
AP - Tue Sep 23, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Amgen Files Blinatumomab Marketing Application in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 4:55PM CDT
Amgen (AMGN) announced that it has submitted a Biologics License Application to the FDA for blinatumomab.
AstraZeneca Posts Positive Data on its Type II Diabetes Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 4:20PM CDT
AstraZeneca (AZN) announced encouraging data from the phase III DURATION-NEO-1 study.
Bayer/Regeneron Successfully Expand Eylea Label in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 3:45PM CDT
Bayer (BAYRY) announced that its blockbuster eye treatment, Eylea, was approved for yet another indication in Japan.
Integra Freedom Wrist's Commercial Availability Falls Flat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 2:10PM CDT
Initially after the news release, Integra LifeSciences' (IART) share price had risen 0.5%. However, the launch failed to sustain this positive price momentum, with shares eventually dropping 0.6% to close at $49.97 yesterday.
Midday Glance: Biotechnology companies
AP - Tue Sep 23, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Sep 23, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
OncoMed Pharmaceuticals (OMED) Jumps: Stock Up 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 7:51AM CDT
OncoMed Pharmaceuticals, Inc. (OMED) was a big mover last session, as its shares rose over 5% on the day.
Most Big Cap 20 Stocks Near Entries, But Risks Exist
at Investor's Business Daily - Mon Sep 22, 6:05PM CDT
Most of the Big Cap 20 stocks are in buy ranges or forming bases. That's an unusually good trend that affords investors plenty of opportunities to deploy capital. But a sluggish market poses risks for any new purchases. For those willing to risk...
Glaxo Fined Roughly $484M in China Bribery Probe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:45PM CDT
GlaxoSmithKline (GSK) announced that it has been found guilty of bribing non-government personnel by the Changsha Intermediate People's Court in Hunan Province, China.
Isis Pharmaceuticals Up on $4M Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:40PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $4 million milestone payment from Achaogen (AKAO), following the initiation of a phase III study on plazomicin.
Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:20PM CDT
The European Commission has approved Gilead's (GILD) Zydelig for the treatment of CLL and FL.
Flexion Continues to Fall Post Clinical Hold on FX006 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:59PM CDT
Flexion announced that the FDA has placed a clinical hold on patient enrollment and dosing in an ongoing phase IIb study on FX006.
Surprising Silver Lining for Gilead Sciences, inc. Stock
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 22, 2:37PM CDT
Shares of Gilead Sciences got knocked down last week after CVS Health released data showing higher discontinuation rates for hepatitis C patients taking Sovaldi than Gilead Sciences saw in its clinical trials. Source: Gilead Sciences ...
Gilead Sciences (GILD) Crosses Pivot Point Support at $105.02
Comtex SmarTrend(R) - Mon Sep 22, 12:27PM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $106.45 today and has reached the first level of support at $105.02. Investors may be interested in a cross of the next downside pivot targets of $104.07 and $101.69.
Gilead Sciences: A Preview of Important HIV Drug Study Results
at The Street - Mon Sep 22, 11:44AM CDT
Gilead's goal is to create new versions of its blockbuster HIV combination therapies, replacing Viread with TAF.
Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
Cytori Therapeutics (CYTX) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:39AM CDT
Cytori Therapeutics, Inc. (CYTX) was a big mover last session, as its shares rose over 6% on the day.
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo
PR Newswire - Mon Sep 22, 8:05AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6643-100free.